These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 23169228

  • 21. [Limits of conventional oral and transdermal medication in Parkinson's disease].
    García-Ruiz PJ, Luquin MR.
    Rev Neurol; 2012; 55 Suppl 1():S3-6. PubMed ID: 23169231
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. New dopaminergic therapies for PD motor complications.
    Larson D, Simuni T.
    Neuropharmacology; 2022 Feb 15; 204():108869. PubMed ID: 34742740
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
    Di Rosa AE, Epifanio A, Antonini A, Stocchi F, Martino G, Di Blasi L, Tetto A, Basile G, Imbesi D, La Spina P, Di Raimondo G, Morgante L.
    Neurol Sci; 2003 Oct 15; 24(3):174-5. PubMed ID: 14598073
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
    Papuć E, Trzciniecka O, Rejdak K.
    Ann Agric Environ Med; 2019 Mar 22; 26(1):133-137. PubMed ID: 30922043
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
    Drapier S, Vérin M.
    Rev Neurol (Paris); 2006 Oct 22; 162(10):1019-23. PubMed ID: 17028572
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
    Bhidayasiri R, Chaudhuri KR, LeWitt P, Martin A, Boonpang K, van Laar T.
    Clin Neuropharmacol; 2015 Oct 22; 38(3):89-103. PubMed ID: 25970277
    [Abstract] [Full Text] [Related]

  • 34. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
    De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, Natuzzi F, Morgante L, Mariani CB, Sganzerla E, Pezzoli G, Antonini A.
    J Neurol Neurosurg Psychiatry; 2006 Apr 22; 77(4):450-3. PubMed ID: 16543520
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 22; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
    Antonini A, Jost WH.
    Fortschr Neurol Psychiatr; 2018 Sep 22; 86(S 01):S5-S9. PubMed ID: 30107620
    [Abstract] [Full Text] [Related]

  • 40. Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review.
    Kukkle PL, Garg D, Merello M.
    Mov Disord Clin Pract; 2023 Sep 22; 10(9):1253-1267. PubMed ID: 37772305
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.